Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, Sharma M, Singh J, Mohapatra J, Chatterjee A, Patel D, Bahekar R, Sharma R, Gupta L, Patel N, Giri P, Srinivas NR, Jain M, Bandyopadhyay D, Patel PR, Desai RC. Ghoshdastidar K, et al. Among authors: srinivas nr. Pharmacol Res Perspect. 2020 Aug;8(4):e00565. doi: 10.1002/prp2.565. Pharmacol Res Perspect. 2020. PMID: 32790160 Free PMC article.
Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
Jain MR, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, Patel A, Bhayani H, Srivastava BK, Shedage SA, Kadam P, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel PR, Desai RC. Jain MR, et al. Among authors: srinivas nr. Cancer Chemother Pharmacol. 2018 Oct;82(4):635-647. doi: 10.1007/s00280-018-3653-1. Epub 2018 Jul 25. Cancer Chemother Pharmacol. 2018. PMID: 30046848
Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model.
Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC. Patel H, et al. Among authors: srinivas nr. Drug Res (Stuttg). 2017 Apr;67(4):223-227. doi: 10.1055/s-0042-122776. Epub 2017 Feb 3. Drug Res (Stuttg). 2017. PMID: 28158894
Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.
Patel H, Joharapurkar AA, Pandya VB, Patel VJ, Kshirsagar SG, Patel P, Gevriya B, Jain MR, Srinivas NR, Patel PR, Desai RC. Patel H, et al. Among authors: srinivas nr. Xenobiotica. 2018 Jan;48(1):37-44. doi: 10.1080/00498254.2016.1278287. Epub 2017 Jan 19. Xenobiotica. 2018. PMID: 28042744
Incurred sample reanalysis in drug discovery bioanalysis.
Giri P, Patel N, Joshi V, Giri S, Srinivas NR. Giri P, et al. Among authors: srinivas nr. Biomed Chromatogr. 2019 Mar;33(3):e4430. doi: 10.1002/bmc.4430. Epub 2018 Dec 6. Biomed Chromatogr. 2019. PMID: 30412644
355 results